4.4 Article

Social Security Work Disability and Its Predictors in Patients With Fibromyalgia

Journal

ARTHRITIS CARE & RESEARCH
Volume 66, Issue 9, Pages 1354-1363

Publisher

WILEY
DOI: 10.1002/acr.22305

Keywords

-

Categories

Funding

  1. Abbott Germany
  2. Pfizer
  3. Daiichi Sankyo

Ask authors/readers for more resources

Objective. To determine prevalence and incidence of US Social Security Disability and Supplemental Security Income (SSD) in patients with fibromyalgia and to investigate prediction of SSD. Methods. Over a mean of 4 years (range 1-13 years), we studied 2,321 patients with physician-diagnosed fibromyalgia (prevalent cases) and applied modified American College of Rheumatology (ACR) 2010 research criteria to identify criteria-positive patients. Results. During the study, 34.8% (95% confidence interval [95% CI] 32.9-36.8%) of fibromyalgia patients received SSD. The annual incidence of SSD among patients not receiving SSD at study enrollment was 3.4% (95% CI 3.0-3.9%), and 25% were estimated to be work disabled at 9.0 years of followup. By comparison, the prevalence of SSD in rheumatoid arthritis (RA) patients with concomitant fibromyalgia was 55.6% (95% CI 54.3-57.0%) and was 42.4% in osteoarthritis (OA). By study conclusion, 31.4% of SSD awardees were no longer receiving SSD. In univariate models, incident SSD in patients with fibromyalgia was predicted by sociodemographic measures and by symptom burden; but the strongest predictor was functional status (Health Assessment Questionnaire disability index [HAQ DI]). In multivariable models, the HAQ DI and the Short Form 36-item health survey physical and mental component summary scores, but no other variables, predicted SSD. Fibromyalgia criteria-positive patients had more SSD, but the continuous scale, polysymptomatic distress index derived from the ACR criteria was a substantially better predictor of SSD than a criteria-positive diagnosis. Conclusion. The prevalence of SSD is high in fibromyalgia, but not higher than in RA and OA patients who satisfy fibromyalgia criteria. The best predictors of work disability are functional status variables.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Rheumatology

The Relation of Physical Comorbidity and Multimorbidity to Fibromyalgia, Widespread Pain, and Fibromyalgia-related Variables

Frederick Wolfe, Jacob Ablin, Emma K. Guymer, Geoffrey O. Littlejohn, Johannes J. Rasker

JOURNAL OF RHEUMATOLOGY (2020)

Article Rheumatology

Modified 2016 American College of Rheumatology Fibromyalgia Criteria, the Analgesic, Anesthetic, and Addiction Clinical Trial Translations Innovations Opportunities and Networks-American Pain Society Pain Taxonomy, and the Prevalence of Fibromyalgia

Winfried Haeuser, Elmar Braehler, Jacob Ablin, Frederick Wolfe

Summary: The prevalence of fibromyalgia in the German general population is 73% greater using the AAPT criteria than the FM 2016 criteria. The AAPT criteria select individuals with less symptom severity and fewer pain sites. The FM 2016 criteria provide a general severity measure for fibromyalgia, but the AAPT criteria do not.

ARTHRITIS CARE & RESEARCH (2021)

Article Rheumatology

Obesity and the Risk of Incident Chronic Opioid Use in Rheumatoid Arthritis

Joshua F. Baker, Andrew Stokes, Sofia Pedro, Ted R. Mikuls, Michael George, Bryant R. England, Harlan Sayles, Fred Wolfe, Kaleb Michaud

Summary: This study found that obese patients with rheumatoid arthritis have a higher rate of incident chronic opioid use. Higher BMI is associated with an increased risk of chronic opioid use, with severe obesity having a higher risk for overall use and strong opioid use. The association between obesity and opioid use may be partially explained by comorbidity, pain, and disability.

ARTHRITIS CARE & RESEARCH (2021)

Article Multidisciplinary Sciences

The relation of fibromyalgia and fibromyalgia symptoms to self-reported seizures

Johannes J. Rasker, Frederick Wolfe, Ewa G. Klaver-Krol, Machiel J. Zwarts, Peter M. ten Klooster

Summary: The study investigated the association between fibromyalgia and self-reported seizures in rheumatoid arthritis patients. Results showed a significant link between FM diagnostic variables, FM-related symptoms, and self-reported seizures, indicating a complex relationship between multi-symptom comorbidity and seizures. Future studies are needed to confirm these findings using validated FM criteria assessments and clinically verified diagnoses of epileptic and psychogenic seizures.

PLOS ONE (2021)

Article Rheumatology

Increase in Cannabis Use Among Adults With Rheumatic Diseases: Results From a 2014-2019 United States Observational Study

Kristin Wipfler, Teresa A. Simon, Patricia Katz, Frederick Wolfe, Kaleb Michaud

Summary: The use of cannabis among rheumatic disease patients significantly increased between 2014 and 2019, with the highest prevalence in states where cannabis was legalized. Most users reported cannabis was effective in relieving arthritis symptoms, but they were more likely to also be taking weak opioids, have a history of tobacco smoking, and had worse patient-reported outcomes overall.

ARTHRITIS CARE & RESEARCH (2022)

Review Clinical Neurology

Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain

Frank Petzke, Thomas Toelle, Mary-Ann Fitzcharles, Winfried Haeuser

Summary: Neuropathic pain is a challenging condition with current medications providing inadequate relief, leading to the consideration of cannabis-based medicines as a treatment option. However, the evidence supporting the use of cannabis-based medicines for chronic neuropathic pain is of low quality, with conflicting conclusions on their efficacy and potential side effects, indicating the need for further research.

CNS DRUGS (2022)

Review Pharmacology & Pharmacy

Cannabis-Based Medicines and Medical Cannabis in the Treatment of Nociplastic Pain

Mary-Ann Fitzcharles, Frank Petzke, Thomas R. Toelle, Winfried Hauser

Summary: Nociplastic pain is characterized by sensitization of the nervous system without a clear anatomical abnormality to explain the pain severity. It is often associated with central nervous system symptoms such as fatigue, cognitive difficulties, and sleep disturbances, as well as other somatic symptoms. The use of cannabinoids, including cannabis-based medicines, for treating nociplastic pain conditions is a potential avenue that warrants further investigation and understanding by healthcare providers.

DRUGS (2021)

Editorial Material Anesthesiology

Register-based studies on cannabis-based medicines and medical cannabis need reliable diagnoses and cannabis treatment details COMMENT

Winfried Haeuser, Mary-Ann Fitzcharles

EUROPEAN JOURNAL OF PAIN (2022)

Review Anesthesiology

Long-term observational studies with cannabis-based medicines for chronic non-cancer pain: A systematic review and meta-analysis of effectiveness and safety

Patric Bialas, Mary-Ann Fitzcharles, Petra Klose, Winfried Haeuser

Summary: This systematic review evaluated the effectiveness, tolerability, and safety of cannabis-based medicines (CbMs) for chronic non-cancer pain (CNCP) in long-term observational studies. The results showed that CbMs had positive effects on multiple symptoms for some CNCP patients and were generally well tolerated and safe. However, the certainty of evidence in observational studies was very low.

EUROPEAN JOURNAL OF PAIN (2022)

Article Anesthesiology

Cannabis use disorder in patients with chronic pain: overestimation and underestimation in a cross-sectional observational study in 3 German pain management centres

Patric Bialas, Claudia Boettge-Wolpers, Mary-Ann Fitzcharles, Sven Gottschling, Dieter Konietzke, Stephanie Juckenhoefel, Albrecht Madlinger, Patrick Welsch, Winfried Haeuser

Summary: There are concerns about the development of cannabis use disorder (CUD) in patients using medical cannabis for chronic pain. The current diagnostic criteria for CUD may not accurately identify patients using cannabis for therapeutic reasons. Alternative strategies are needed to determine the true prevalence of CUD in chronic pain patients treated with medical cannabis. In a study conducted in three German pain centers, the prevalence of CUD in chronic pain patients prescribed medical cannabis was assessed using anonymous questionnaires.
Article Rheumatology

Emotion regulation and the salience network: a hypothetical integrative model of fibromyalgia

Ana Margarida Pinto, Rinie Geenen, Tor D. Wager, Mark A. Lumley, Winfried Hauser, Eva Kosek, Jacob N. Ablin, Kirstine Amris, Jaime Branco, Dan Buskila, Joao Castelhano, Miguel Castelo-Branco, Leslie J. Crofford, Mary-Ann Fitzcharles, Marina Lopez-Sola, Mariana Luis, Tiago Reis Marques, Philip J. Mease, Filipe Palavra, Jamie L. Rhudy, Lucina Q. Uddin, Paula Castilho, Johannes W. G. Jacobs, Jose A. P. da Silva

Summary: This article presents a new model called FITSS (Fibromyalgia: Imbalance of Threat and Soothing Systems), which proposes that an imbalance in emotion regulation, specifically an overactive 'threat' system and underactive 'soothing' system, may contribute to the development of fibromyalgia. This model provides a new perspective for future research and may stimulate the discovery of novel therapeutic interventions.

NATURE REVIEWS RHEUMATOLOGY (2023)

Article Rheumatology

Looking at fibromyalgia differently-An observational study of the meaning and consequences of fibromyalgia as a dimensional disorder

Frederick Wolfe, Kaleb Michaud, Peter M. ten Klooster, Johannes J. Rasker

Summary: By studying categorical diagnosis, polysymptomatic distress scale, and clinical variables, we found that fibromyalgia is more accurately considered as a dimensional rather than a dichotomous disorder. The polysymptomatic distress scale provides valuable measurements of the fibromyalgia dimension and is effective in assessing clinical status and changes.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2023)

Letter Rheumatology

To the Editor

Frederick Wolfe, Johannes J. Rasker

SEMINARS IN ARTHRITIS AND RHEUMATISM (2023)

Letter Rheumatology

Fibromyalgia criteria and anomalous results: comment on the article by Ghavidel-Parsa et al

Frederick Wolfe, Johannes J. Rasker, Winfried Haeuser

ACR OPEN RHEUMATOLOGY (2022)

Article Rheumatology

Fibromyalgia revisited: do latent class analyses of symptom profiles in the general population confirm 2016 fibromyalgia diagnostic criteria?

B. Schmalbach, W. Haeuser, E. Brahler, P. Henningsen, F. Wolfe

Summary: Two somatic symptom profiles consistent with the 2016 FM diagnostic criteria were identified in the general German population, differing in somatic and psychological symptom burden and general health, supporting the distinction of FM severities.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY (2021)

No Data Available